Compare · NVS vs SYRE
NVS vs SYRE
Side-by-side comparison of Novartis AG (NVS) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $296.16B, about 30.7x SYRE ($9.64B).
- Both names hit the wire about 5 times in the past 4 weeks.
- NVS has more recent analyst coverage (25 ratings vs 13 for SYRE).
- Company
- Novartis AG
- Spyre Therapeutics Inc.
- Price
- -
- -
- Market cap
- $296.16B
- $9.64B
- 1M return
- +1.07%
- -
- 1Y return
- +21.96%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 13
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest SYRE
- Spyre Therapeutics to Participate in Upcoming Investor Conferences
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Spyre Therapeutics Inc.
- Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
- UBS initiated coverage on Spyre Therapeutics with a new price target
- SEC Form 8-K filed by Spyre Therapeutics Inc.
- SEC Form 424B5 filed by Spyre Therapeutics Inc.
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock